High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance

Journal of Viral Hepatitis
P AndreoneM Bernardi

Abstract

The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However, its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive behaviour, and one in the nine long-term responder patients (P = 0.013). Lamivudine resistance was the only independent predictor of hepatocellular carcinoma development (risk ratio: 10.4; 95% CI: 1.3-84.9). Our study suggests that the occurrence of lamivudine resistance increases the risk of hepatocellular carcinoma in anti-HBe positive cirrhosis and warrants further research.

References

Mar 14, 1996·The New England Journal of Medicine·V MazzaferroL Gennari
Feb 14, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M MelegariJ R Wands
Jun 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K ChayamaH Kumada
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N C TassopoulosD F Gray
Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y F LiawC M Chu
Sep 25, 1999·Journal of Cellular Physiology·M A Feitelson
Aug 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P HonkoopS W Schalm
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D T LauJ H Hoofnagle
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S J HadziyannisC Papaioannou
Oct 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A S LokP Andreone
May 29, 2001·Gastroenterology·A S LokJ H Hoofnagle
Sep 14, 2001·Journal of Viral Hepatitis·G V Papatheodoridis, S J Hadziyannis
Apr 6, 2002·Digestive Diseases·C RabeW H Caselmann
Nov 25, 2003·Journal of Medical Virology·Baiqing TangAlison A Evans
Jan 8, 2004·Journal of Hepatology·Mario RizzettoMarco Lagget

❮ Previous
Next ❯

Citations

Dec 29, 2009·Frontiers in Bioscience (Scholar Edition)·Baruch S Blumberg
Dec 5, 2008·Expert Review of Anti-infective Therapy·Ioannis Goulis, George N Dalekos
Nov 4, 2009·Expert Review of Anti-infective Therapy·Stevan A Gonzalez, Emmet B Keeffe
Aug 20, 2008·Expert Opinion on Pharmacotherapy·Mark A FeitelsonEva Ping Lu
Aug 20, 2011·Clinical Biochemistry·Kaimin ChanVivian Chan
Sep 30, 2009·Virus Research·Ruth ChinJoseph Torresi
Sep 15, 2006·Clinics in Liver Disease·Scott K Fung, Robert J Fontana
Jun 10, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Morris ShermanUNKNOWN AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group
Feb 16, 2007·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Shoji KuboShuhei Nishiguchi
Apr 1, 2006·Alimentary Pharmacology & Therapeutics·M Sherman
Feb 15, 2013·Journal of Medical Virology·Maria Neumann-FrauneJens Verheyen
Jun 12, 2010·Annals of the New York Academy of Sciences·A Ciancio, M Rizzetto
Jun 10, 2006·Gastroenterology·Morris ShermanUNKNOWN AI463026 BEHoLD Study Group
Mar 11, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emmet B KeeffeYves Benhamou
Aug 31, 2010·Gastroenterology·Theodora E M S de Vries-SluijsMarchina E van der Ende
Sep 5, 2018·European Journal of Gastroenterology & Hepatology·Evangelos StournarasKonstantinos Tziomalos
Oct 31, 2019·Expert Review of Gastroenterology & Hepatology·Ming-Wei Lai, Mei-Hwei Chang
Jul 31, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Raph L HamersUNKNOWN PharmAccess African Studies to Evaluate Resistance (PASER)
Aug 4, 2009·Cadernos de saúde pública·Alessandra Maciel AlmeidaFrancisco de Assis Acurcio
May 19, 2020·Antiviral Chemistry & Chemotherapy·Mohamed A Abd El AzizAntonio Facciorusso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Vito Di MarcoItalian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy
The New England Journal of Medicine
Yun-Fan LiawCirrhosis Asian Lamivudine Multicentre Study Group
JAMA : the Journal of the American Medical Association
Chien-Jen ChenREVEAL-HBV Study Group
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Y F LiawC M Chu
© 2021 Meta ULC. All rights reserved